Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support



Status:Recruiting
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:8/30/2018
Start Date:January 3, 2018
End Date:June 2019
Contact:Visterra
Email:VIS410-203@visterrainc.com
Phone:617-498-1070

Use our guide to learn which trials are right for you!

Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs
oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
support.

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs
oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
support. Subjects will be followed for 56 days.

Inclusion Criteria:

- Male and female subjects aged ≥ 18 years.

- Test positive for influenza A by rapid antigen test or with another commercially
available test on an adequate nasopharyngeal specimen in accordance with the
manufacturer's instructions, or an acceptable local test, including PCR, FIA, or ELISA

- Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion;
symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal
symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.

- Requirement for oxygen support including any positive pressure ventilation

- Women of childbearing potential must have a negative pregnancy test within 2 days
prior to VIS410/placebo infusion.

- Women should fulfill one of the following criteria:

- Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone >
40 mIU/mL as documented in their medical history

- Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation

- Women of childbearing potential participating in heterosexual sexual relations
must be willing to use adequate contraception from screening until 60 days post
VIS410/placebo infusion.

- Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects
who have a female partner of childbearing potential must use an effective birth
control method from screening until 60 days post VIS410/placebo infusion.

- Subject, or a legally acceptable representative (LAR), is able to understand the
purpose and risks of the study and willing to give voluntary written informed consent.

Exclusion Criteria:

- Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir,
pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic
acid [ASA]), or closely related compounds (eg, other monoclonal antibodies)

- Subjects who have received VIS410 in the past

- History of receiving monoclonal antibody products (including VIS410) within 3 months
prior to VIS410/placebo dosing or planned administration during the study period

- Subjects who have taken more than 6 doses of an approved antiviral therapy for
influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV
peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing

- Subjects with known co-infection with influenza B or other viral respiratory
infections (e.g., respiratory syncytial virus, parainfluenza viruses, respiratory
adenoviruses)

- Subjects with lung transplant or history of severe chronic lung disease, including
cystic fibrosis or any condition requiring home oxygen therapy

- Subjects on extracorporeal membrane oxygenation (ECMO) at time of randomization

- Subjects with end stage renal disease who are not undergoing hemodialysis

- Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within
the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count
of less than 200 per cubic millimeter

- Hospitalization for > 48 hours prior to randomization

- High probability of mortality within 48 hours of randomization as determined by the
Investigator

- Subjects weighing less than 45 kg

- Enrollment in any other investigational drug or device study, any disease or vaccine
study within 30 days prior to Day 1 or within 5 half-lives of the investigational
compound, whichever is longer

- Known or suspected alcohol or drug abuse, that is, abuse of a level that would
compromise the safety or cooperation of the subject in the opinion of the Investigator
We found this trial at
22
sites
275 2nd Avenue
York, Pennsylvania 17405
Phone: 617-498-1070
?
mi
from
York, PA
Click here to add this to my saved trials
Adelaide, South Australia
Phone: 617-498-1070
?
mi
from
Adelaide,
Click here to add this to my saved trials
43 New Scotland Avenue
Albany, New York 12208
Phone: 617-498-1070
?
mi
from
Albany, NY
Click here to add this to my saved trials
1200 South Cedar Crest Boulevard
Allentown, Pennsylvania 18103
Phone: 617-498-1070
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Phone: 617-498-1070
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Blackfoot, Idaho 83221
Phone: 617-498-1070
?
mi
from
Blackfoot, ID
Click here to add this to my saved trials
Butte, Montana 59701
Phone: 617-498-1070
?
mi
from
Butte, MT
Click here to add this to my saved trials
Chicago, Illinois 60637
Phone: 617-498-1070
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44195
Phone: 617-498-1070
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43215
Phone: 617-498-1070
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Decatur, Georgia 30033
Phone: 617-498-1070
?
mi
from
Decatur, GA
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 617-498-1070
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27710
Phone: 617-498-1070
?
mi
from
Durham, NC
Click here to add this to my saved trials
3030 High Point Road
Greensboro, North Carolina 27403
Phone: 617-498-1070
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19141
Phone: 617-498-1070
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Richland, Washington 99352
Phone: 617-498-1070
?
mi
from
Richland, WA
Click here to add this to my saved trials
Roanoke, Virginia 24014
Phone: 617-498-1070
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
2909 22nd Avenue North
Saint Petersburg, Florida 33713
Phone: 617-498-1070
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Stanford, California 94305
Phone: 617-498-1070
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Syracuse, New York 13210
Phone: 617-498-1070
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Tacoma, Washington 98405
Phone: 617-498-1070
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tucson, Arizona 85724
Phone: 617-498-1070
?
mi
from
Tucson, AZ
Click here to add this to my saved trials